CSF1R defines the mononuclear phagocyte system lineage in human blood in health and COVID-19.

CSF1R defines the mononuclear phagocyte system lineage in human blood in health and COVID-19.
复制标题

DOI:
10.1093/immadv/ltab003
复制
发表时间:
2021-01
影响因子:
--
通讯作者:
Martinez FO
Martinez FO
中科院分区:
其他
文献类型:
--
作者:
Combes TW;Orsenigo F;Stewart A;Mendis ASJR;Dunn-Walters D;Gordon S;Martinez FO

文献摘要

参考文献

被引文献

相似文献

单核巨噬细胞保护组织,呈递抗原,并介导恢复和愈合。到目前为止,我们还缺乏一个标记来统一人类中的单核巨噬细胞,或者告诉我们它们的来源。在这里,我们通过谱系受体CSF1R,在稳态和新冠肺炎中重新评估人类血液中单核吞噬细胞的个体发育。我们将CSF1R定义为第一个敏感且可重现的泛噬细胞系标记物,用于识别和计数所有常规单核细胞和髓系树突状细胞。在稳定状态下,CSF1R足以进行分选和免疫磁隔离。在病理上,CSF1R的变化比CD14和CD16更敏感。在新冠肺炎中,细胞膜CSF1R的显著下降对于患者分层是有用的,这超出了迄今公布的细胞类别的能力,因为这些细胞类别未能捕捉到新冠肺炎的具体事件。重要的是,CSF1R定义了既不是传统的单核细胞也不是DC的细胞,这在已发表的分析中被遗漏了。CSF1R的减少可能与体外高水平的CSF1有关。对CSF1R+细胞的血液评估打开了一个发展窗口,了解从骨髓到组织的单核吞噬系统,支持分离和表型鉴定,识别新的细胞类型,并挑出CSF1R抑制作为新冠肺炎和其他疾病的治疗靶点。
Mononuclear phagocytes defend tissues, present antigens, and mediate recovery and healing. To date, we lack a marker to unify mononuclear phagocytes in humans or that informs us about their origin. Here, we reassess mononuclear phagocyte ontogeny in human blood through the lineage receptor CSF1R, in the steady state and in COVID-19. We define CSF1R as the first sensitive and reproducible pan-phagocyte lineage marker, to identify and enumerate all conventional monocytes, and the myeloid dendritic cells. In the steady state, CSF1R is sufficient for sorting and immuno-magnetic isolation. In pathology, changes in CSF1R are more sensitive than CD14 and CD16. In COVID-19, a significant drop in membrane CSF1R is useful for stratifying patients, beyond the power of cell categories published thus far, which fail to capture COVID-19 specific events. Importantly, CSF1R defines cells which are neither conventional monocytes nor DCs, which are missed in published analysis. CSF1R decrease can be linked ex vivo to high CSF1 levels. Blood assessment of CSF1R+ cells opens a developmental window to the Mononuclear Phagocyte System in transit from bone marrow to tissues, supports isolation and phenotypic characterisation, identifies novel cell types, and singles out CSF1R inhibition as therapeutic target in COVID-19 and other diseases.
DOI: 10.1084/jem.20170355
发表时间: 2017-07-03
期刊: The Journal of experimental medicine
影响因子: --
作者:
Patel AA;Zhang Y;Fullerton JN;Boelen L;Rongvaux A;Maini AA;Bigley V;Flavell RA;Gilroy DW;Asquith B;Macallan D;Yona S
通讯作者: Yona S
DOI: 10.1111/imr.12223
发表时间: 2014-11
影响因子: 8.7
作者:
Gordon S;Plüddemann A;Martinez Estrada F
通讯作者: Martinez Estrada F
DOI: 10.1182/blood.v95.1.270
发表时间: 2000-01-01
期刊: BLOOD
影响因子: 20.3
作者:
Boneberg, EM;Hareng, L;Hartung, T
通讯作者: Hartung, T
DOI: 10.1016/j.immuni.2019.08.008
发表时间: 2019-09-17
期刊: IMMUNITY
影响因子: 32.4
作者:
Dutertre, Charles-Antoine;Becht, Etienne;Ginhoux, Florent
通讯作者: Ginhoux, Florent
DOI: 10.1016/j.ebiom.2020.102964
发表时间: 2020-09-01
期刊: EBIOMEDICINE
影响因子: 11.1
作者:
Martinez, Fernando O.;Combes, Theo W.;Gordon, Siamon
通讯作者: Gordon, Siamon